Skip to content

US · CERS · MEDICAL - DEVICES

Cerus Corporation (CERS) intrinsic value and stock valuation

$1.85as of 2026-11-21 · Mkt cap 457.46M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cerus Corporation DCF and intrinsic value

InvestorsCraft values CERS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CERS’s statements →

Cerus Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Concord, CA 94520 cerus.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$206.1M+17.5% 5y CAGRd
20112025
Net income
-$-15.63M
20112025
Free cash flow
$8.52M
20112025
Total equity
$65M-8.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$206.1M$180.3M$156.4M$162.1M$130.9M
Operating income-$-8.68M-$-14.22M-$-30.05M-$-34.08M-$-48.94M
Net income-$-15.63M-$-20.92M-$-37.49M-$-42.78M-$-54.37M
EPSd-$-82.01K-$-113.35K-$-207.97K-$-242.32K-$-317.43K
Operating cash flow$11.4M$11.4M-$-43.17M-$-25.61M-$-33.92M
Capital expenditure-$-2.84M-$-2.84M-$-4.6M-$-2M-$-910K
Free cash flow$8.52M$8.52M-$-47.77M-$-27.61M-$-34.83M
Total assets$221.9M$200.9M$197.8M$218.1M$237.5M
Total debt$97M$98.1M$96M$87.2M$87.6M
Net debt$77M$77.8M$84.4M$51.7M$38.8M
Total equity$65M$56.9M$53.4M$68.6M$85.6M
Cash and short-term investments$82.9M$80.5M$65.9M$102.2M$129.4M
Income statement
20252024202320222021
Revenue$206.1M$180.3M$156.4M$162.1M$130.9M
Cost of revenue$93.8M$80.8M$70M$75M$63.5M
Gross profit$112.3M$99.5M$86.4M$87.1M$67.4M
Research and development expenses$67.7M$58.9M$67.6M$64.1M$63.7M
Selling, general and administrative expenses$80.9M$75.9M$75.5M$83.3M$81.3M
Other expenses-$-27.66M-$-21.05M-$-26.7M-$-26.27M-$-28.66M
Operating expenses$121M$113.8M$116.5M$121.2M$116.3M
Cost and expenses$214.8M$194.5M$186.4M$196.1M$179.8M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$8.34M$8.88M$8.39M$5.83M$4.92M
Depreciation and amortization$1.43M$1.85M$2.6M$2.98M$3.15M
Ebitda-$-5.51M-$-10.02M-$-26.34M-$-33.52M-$-45.99M
Operating income-$-8.68M-$-14.22M-$-30.05M-$-34.08M-$-48.94M
Total other income/expenses, net-$-6.6M-$-6.53M-$-7.27M-$-8.26M-$-5.12M
Income before tax-$-15.28M-$-20.76M-$-37.32M-$-42.34M-$-54.06M
Income tax expense$350K$200K$330K$490K$320K
Net income-$-15.63M-$-20.92M-$-37.49M-$-42.78M-$-54.37M
Weighted average shares outstanding$190.6M$184.6M$180.3M$176.5M$171.3M
Weighted average diluted shares outstanding$190.6M$184.6M$180.3M$176.5M$171.3M
Balance sheet
20252024202320222021
Cash and short-term investments$82.9M$80.5M$65.9M$102.2M$129.4M
Net receivables$30.4M$29.8M$35.5M$34.4M$25.1M
Inventory$56.1M$38.2M$39.9M$29M$26.8M
Total current assets$174.4M$152M$144.4M$170.1M$187.1M
Property, plant and equipment, net$19.3M$15.5M$19.4M$23.5M$25.2M
Goodwill and intangible assets$1.32M$1.32M$1.32M$1.32M$1.32M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$47.5M$48.9M$53.3M$48M$50.4M
Total assets$221.9M$200.9M$197.8M$218.1M$237.5M
Accounts payable$28M$21.7M$23.8M$33M$35.6M
Short-term debt$46.3M$21.6M$22.5M$58.3M$16.6M
Deferred revenue$1.27M$1.4M$2M$590K$670K
Total current liabilities$100.8M$63.6M$67.5M$117.1M$78.6M
Long-term debt$50.7M$76.5M$73.6M$29M$71M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$56.1M$80.4M$76.8M$32.5M$73.3M
Capital lease obligations$13.1M$13.9M$16.2M$17.4M$18.2M
Total liabilities$156.9M$144M$144.3M$149.5M$151.9M
Common stock$190K$190K$180K$180K$170K
Retained earnings-$-1.08B-$-1.07B-$-1.04B-$-1.01B-$-964.34M
Accumulated other comprehensive income (loss)-$-160K-$-400K-$-1.27M-$-2.79M-$-150K
Total equity$65M$56.9M$53.4M$68.6M$85.6M
Total investments$62.9M$60.2M$54.2M$66.6M$80.6M
Total debt$97M$98.1M$96M$87.2M$87.6M
Net debt$77M$77.8M$84.4M$51.7M$38.8M
Cash flow statement
20252024202320222021
Net income-$-15.63M-$-20.96M-$-37.49M-$-42.83M-$-54.38M
Depreciation and amortization$1.85M$1.85M$2.6M$2.98M$3.15M
Stock-based compensation$22.9M$22.9M$20.3M$24.5M$23.6M
Change in working capital-$-6.83M$5.23M-$-32.03M-$-16.05M-$-9.4M
Accounts receivable-$-400K$5.5M-$-1.1M-$-9.2M-$-4.21M
Inventory-$-14.68M$7.03M-$-14.95M-$-1.77M-$-19.61M
Accounts payable$5.72M-$-1.48M-$-7.33M-$-4.91M$12.2M
Net cash provided by operating activities$11.4M$11.4M-$-43.17M-$-25.61M-$-33.92M
Investments in property, plant and equipment-$-2.84M-$-2.84M-$-4.6M-$-2M-$-910K
Acquisitions, net$0.00$0.00$0.00-$-10.46M$910K
Net cash used for investing activities-$-8.13M-$-8.13M$8.62M$8.46M$12.7M
Common stock issued$560K$670K$0.00$0.00$2.74M
Common stock repurchased$0.00$0.00-$-170K-$-100K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.96M$4.96M$10.7M$4.19M$34.3M
Net change in cash$8M$8M-$-24M-$-13.69M$12.1M
Cash at end of period$21.4M$21.4M$13.4M$37.4M$51M
Operating cash flow$11.4M$11.4M-$-43.17M-$-25.61M-$-33.92M
Capital expenditure-$-2.84M-$-2.84M-$-4.6M-$-2M-$-910K
Free cash flow$8.52M$8.52M-$-47.77M-$-27.61M-$-34.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cerus Corporation

        Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.

        CEO
        Vivek K. Jayaraman
        Employees
        275
        Beta
        1.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Cerus Corporation (CERS)?

        Cerus Corporation (CERS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CERS undervalued?

        CERS trades at a price of $1.85 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.